Ketokonazol - Den starka CYP3A4/ 5- hämmaren ketokonazol ökade den systemiska exponeringen av lasofoxifen med 20%, vilket inte betraktas som kliniskt relevant. ###>4 Ketoconazole - The strong CYP3A4/ 5 inhibitor ketoconazole increased the systemic exposure of lasofoxifene by 20% which is not considered to be clinically meaningful.